Le Lézard
Classified in: Health
Subjects: TDS, TRI, FVT

Lakewood-Amedex, Inc. to Present at 2018 BIO CEO & Investor Conference


SARASOTA, Fla., Feb. 8, 2018 /PRNewswire/ -- Lakewood-Amedex, Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City.

Steve Parkinson, President and CEO of Lakewood-Amedex, plans to present data on the Company's lead therapeutic candidate, Nu-3, a topically applied antimicrobial which recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU). The presentation will also highlight the Company's second drug candidate, Nu-8, which Lakewood-Amedex anticipates advancing into preclinical IND-enabling studies following positive pre-IND written communications with the FDA. Nu-8 will be developed for the treatment of complicated urinary tract infections (cUTI) that are currently treated with systemic orally delivered antibiotics.

Lakewood-Amedex Presentation Details:
Date: Tuesday, February 13, 2018
Time: 9:45 AM (Eastern Time)
Location: New York Marriott Marquis, Gilbert Room

An audio webcast will be accessible for 90 days following the presentation via the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2018/58208329358.cfm 

About Lakewood-Amedex, Inc.
Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The Company's products and technology are covered by an extensive patent portfolio consisting of over 100 granted and/or issued patents and 4 pending patent applications covering many major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and has recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU).

Contacts:
Tiberend Strategic Advisors, Inc.
Jonathon Brzezinski, Ph.D. (investors)
[email protected] 
(212) 375-2681

Tiberend Strategic Advisors, Inc.
David Schemelia (media)
[email protected] 
(212) 375-2686

SOURCE Lakewood-Amedex, Inc.


These press releases may also interest you

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...



News published on and distributed by: